R-Pharm by Alexei Repik topped the rating of pharmaceutical manufacturers who earned the most from the sale of coronavirus drugs through state purchases in 10 months of 2021. This is stated in a study by DSM Group, which it conducted at the request of Vedomosti. It says that the company gained almost 25 billion rubles, which is a quarter of all funds spent by the state on the purchase of drugs recommended by the Ministry of Health. We are talking about 28 international non-proprietary names (INN) included in the guidelines for the prevention and treatment of infection dated October 14, 2021.
For 10 months of 2021, the volume of purchases of drugs recommended by the Ministry of Health for the needs of hospitals increased 6.5 times compared to the same period last year, amounting to 95.8 billion rubles. Three quarters of these funds were distributed among 10 pharmaceutical companies. In addition to R-Pharma (26%), these are Biocad (8.6%), Pfizer (6.6%), Bayer (6.4%), Promomed Rus (5.4%), F Hoffmann-La Roche (5.2%), Aspen Pharma (4.4%), Pharmasintez (4.3%), Protek (4.2%) and Eli Lilly (3.6%).
.